Condition: Recurrent Non-Muscle Invasive Bladder Carcinoma · Stage 0a Bladder Cancer AJCC v8 · Stage 0is Bladder Cancer AJCC v8 · Sponsor: University of California, Davis
This phase I trial tests the safety, tolerability and effectiveness of PLZ4-coated paclitacel-loaded micelles (PPM) in treating patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory). PPM is a bladder cancer-specific nanoparticle that can specifically target and deliver treatment to the tumor cells in the bladder. PPM contains paclitaxel, which is a drug that kills tumor cells or keeps them from growing.
This description comes directly from the study's public registry record.
Office of Clinical Research · 916-382-6970 · OCRReferral@health.ucdavis.edu
Always discuss trial participation with your own doctor first.
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06173349